ATE322249T1 - System zur abgabe einer tobramycin-formulierung - Google Patents

System zur abgabe einer tobramycin-formulierung

Info

Publication number
ATE322249T1
ATE322249T1 AT02771857T AT02771857T ATE322249T1 AT E322249 T1 ATE322249 T1 AT E322249T1 AT 02771857 T AT02771857 T AT 02771857T AT 02771857 T AT02771857 T AT 02771857T AT E322249 T1 ATE322249 T1 AT E322249T1
Authority
AT
Austria
Prior art keywords
delivery system
formulation delivery
tobramycin
less
tobramycin formulation
Prior art date
Application number
AT02771857T
Other languages
English (en)
Inventor
Robert J Speirs
Barbara A Schaeffler
Peter B Challoner
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23123791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE322249(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE322249T1 publication Critical patent/ATE322249T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT02771857T 2001-05-18 2002-05-17 System zur abgabe einer tobramycin-formulierung ATE322249T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29223401P 2001-05-18 2001-05-18

Publications (1)

Publication Number Publication Date
ATE322249T1 true ATE322249T1 (de) 2006-04-15

Family

ID=23123791

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02771857T ATE322249T1 (de) 2001-05-18 2002-05-17 System zur abgabe einer tobramycin-formulierung

Country Status (11)

Country Link
US (8) US20030143162A1 (de)
EP (2) EP1320355B1 (de)
JP (2) JP2004534763A (de)
AT (1) ATE322249T1 (de)
AU (1) AU2010210026A1 (de)
CA (1) CA2447600C (de)
DE (1) DE60210402T2 (de)
DK (1) DK1320355T3 (de)
ES (1) ES2261735T3 (de)
PT (1) PT1320355E (de)
WO (1) WO2002094217A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW465235B (en) 1998-09-17 2001-11-21 United Video Properties Inc Electronic program guide with digital storage
ATE322249T1 (de) * 2001-05-18 2006-04-15 Chiron Corp System zur abgabe einer tobramycin-formulierung
US20040022740A1 (en) * 2001-07-10 2004-02-05 Baker William R. Macrolide formulations for inhalation and methods of treatment of endobronchial infections
CA2456746A1 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US7368102B2 (en) 2001-12-19 2008-05-06 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7334580B2 (en) * 2002-05-07 2008-02-26 Smaldone Gerald C Methods, devices and formulations for targeted endobronchial therapy
US7607436B2 (en) * 2002-05-06 2009-10-27 The Research Foundation Of State University Of New York Methods, devices and formulations for targeted endobronchial therapy
US9186322B2 (en) * 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
CN1681478A (zh) * 2002-08-02 2005-10-12 川塞夫有限公司 铂聚集体及其制备方法
AU2002953095A0 (en) * 2002-11-29 2002-12-19 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
EP1638549A4 (de) 2003-03-10 2011-06-15 Optimer Pharmaceuticals Inc Neue antibakterielle mittel
CA2541849C (en) * 2003-10-15 2012-07-31 Pari Gmbh Liquid preparation containing tobramycin
AU2005223654A1 (en) * 2004-03-18 2005-09-29 Transave, Inc. Administration of cisplatin by inhalation
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
BRPI0509026A (pt) 2004-05-17 2007-09-18 Corus Pharma Inc formulação de aerossol, método para a prevenção e tratamento de infecção causada por bactéria do trato respiratório, e, solução
US20060034906A1 (en) * 2004-05-21 2006-02-16 Transave, Inc. Treatment of lung diseases and pre-lung disease conditions
US20080214481A1 (en) 2004-06-18 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Methods of Treatment of Endobronchial Infections
EP1811963A4 (de) * 2004-11-08 2010-01-06 Transave Inc Verfahren zur krebsbehandlung mit intraperitoneal verabreichten platinverbindungsformulierungen auf lipidbasis
WO2007041156A2 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
AU2013206401B2 (en) * 2005-09-29 2016-06-23 Novartis Ag Antibiotic formulations, unit doses, kits, and methods
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007056236A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
WO2007056263A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously
WO2007056264A2 (en) * 2005-11-08 2007-05-18 Transave, Inc. Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
WO2007064658A2 (en) * 2005-11-30 2007-06-07 Transave, Inc. Safe and effective methods of administering therapeutic agents
JP5324223B2 (ja) 2005-12-08 2013-10-23 トランセイブ， インク． 肺感染症を治療する抗感染薬の脂質ベースの組成物及びその使用法
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
JP2008199905A (ja) * 2007-02-16 2008-09-04 Snow Brand Milk Prod Co Ltd 乳酸菌生残性向上剤
CA2703475A1 (en) 2007-10-25 2009-04-30 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
US20110049634A1 (en) * 2008-04-02 2011-03-03 Nxp B.V. Method of manufacturing a semiconductor device and semiconductor device
US8796232B2 (en) * 2008-10-24 2014-08-05 Cempra Pharmaceuticals, Inc. Methods for treating resistant diseases using triazole containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
JP5914335B2 (ja) 2009-09-10 2016-05-11 センプラ ファーマシューティカルズ，インコーポレイテッド マラリア、結核、及びｍａｃ病の治療方法
CN103080122A (zh) 2010-03-22 2013-05-01 森普拉制药公司 大环内脂的结晶形式及其用途
WO2011146829A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
US8598131B2 (en) * 2010-07-12 2013-12-03 Xellia Pharmaceuticals Aps Method for treatment of lung infections by administration of aminoglycosides by aerolisation
JP6042334B2 (ja) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド 疾患治療のための水素結合形成フルオロケトライド
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
CA2841272C (en) 2011-07-12 2019-01-15 Alan Bruce Montgomery Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis
CN104470527B (zh) 2012-03-27 2019-05-28 森普拉制药公司 用于施用大环内酯抗生素的肠胃外制剂
GB201208080D0 (en) 2012-05-09 2012-06-20 Norton Healthcare Ltd Tobramycin formulation
PL2892524T3 (pl) 2012-09-04 2021-10-25 Eleison Pharmaceuticals, Llc Zapobieganie nawrotom płucnym przy użyciu cisplatyny w kompleksie z lipidami
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
AU2014204873B2 (en) 2013-01-11 2017-07-06 Xellia Pharmaceuticals Aps Polymyxins, compositions, methods of making and methods of use
RU2015138796A (ru) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. Способы и составы для лечения респираторных заболеваний
WO2014145210A1 (en) 2013-03-15 2014-09-18 Cempra Pharmaceuticals, Inc. Convergent processes for preparing macrolide antibacterial agents
SMT202000516T1 (it) 2014-05-15 2020-11-10 Insmed Inc Metodi per trattamento di infezioni micobatteriche polmonati non tubercolari
CN106661090A (zh) 2014-07-09 2017-05-10 埃克斯利亚制药有限公司 低取代的多粘菌素以及它们的组合物
BR112017006848B1 (pt) 2014-10-03 2022-10-04 Xellia Pharmaceuticals Aps Composições
RS58792B1 (sr) 2014-10-03 2019-07-31 Xellia Pharmaceuticals Aps Inhalacioni uređaj
US10617703B2 (en) 2014-12-10 2020-04-14 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US10898455B2 (en) 2016-01-07 2021-01-26 Cmpd Licensing, Llc Urea cream formulations
US11690815B2 (en) 2015-08-05 2023-07-04 Cmpd Licensing Llc Hyperkeratotic skin condition treatments and compositions
US10898491B2 (en) 2015-12-18 2021-01-26 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11278590B2 (en) 2015-08-05 2022-03-22 Cmpd Licensing, Llc Compositions and methods for treating nail infections
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US10525025B2 (en) 2016-11-17 2020-01-07 Cmpd Licensing, Llc Compounded compositions and methods for treating pain
US9999604B2 (en) 2016-11-17 2018-06-19 Cmpd Licensing, Llc Compounded solutions of diclofenac and lidocaine and methods
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
WO2019213398A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
WO2020163416A1 (en) * 2019-02-05 2020-08-13 Mylan Inc Devices and methods for tobramycin inhalation treatment

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993223A (en) 1974-07-25 1976-11-23 American Home Products Corporation Dispensing container
US4502616A (en) 1982-01-04 1985-03-05 Health Care Concepts, Inc. Single use vial
GB8801655D0 (en) 1988-01-26 1988-02-24 Waverley Pharma Ltd Ampoules
ES2038445T3 (es) 1988-01-28 1993-07-16 Lameplast S.R.L. Tiras de ampollas para productos farmaceuticos, cosmeticos y otros.
GB8802349D0 (en) 1988-02-03 1988-03-02 Waverley Pharma Ltd Ampoule with luer
DE3916840A1 (de) 1988-09-21 1990-03-29 Bernd Hansen Ampulle
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
CA2027690A1 (en) 1990-10-18 1992-04-19 Christian Laing Plastic ampul
FR2687066A1 (fr) 1992-02-06 1993-08-13 Oreal Ampoule autocassable.
US5508269A (en) * 1994-10-19 1996-04-16 Pathogenesis Corporation Aminoglycoside formulation for aerosolization
US5758637A (en) * 1995-08-31 1998-06-02 Aerogen, Inc. Liquid dispensing apparatus and methods
US6083922A (en) 1996-04-02 2000-07-04 Pathogenesis, Corp. Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis
BR9916296A (pt) * 1998-12-17 2004-06-29 Pathogenesis Corp Método para tratamento de bronquite crÈnica severa (bronquiectase) com um antibiótico em forma de aerossol
SE9902627D0 (sv) * 1999-07-08 1999-07-08 Siemens Elema Ab Medical nebulizer
DE19953317C1 (de) 1999-11-05 2001-02-01 Pari Gmbh Inhalationsvernebler
ATE322249T1 (de) 2001-05-18 2006-04-15 Chiron Corp System zur abgabe einer tobramycin-formulierung

Also Published As

Publication number Publication date
EP1320355B1 (de) 2006-04-05
CA2447600C (en) 2015-10-20
JP2004534763A (ja) 2004-11-18
US6890907B2 (en) 2005-05-10
US8507454B2 (en) 2013-08-13
JP2009269923A (ja) 2009-11-19
US20040131555A1 (en) 2004-07-08
WO2002094217A1 (en) 2002-11-28
US20120101055A1 (en) 2012-04-26
DE60210402T2 (de) 2006-12-07
US20110005518A1 (en) 2011-01-13
DE60210402D1 (de) 2006-05-18
PT1320355E (pt) 2006-08-31
EP2186508A3 (de) 2010-08-25
AU2010210026A1 (en) 2010-09-02
US7825095B2 (en) 2010-11-02
CA2447600A1 (en) 2002-11-28
US20050207987A1 (en) 2005-09-22
EP2186508A2 (de) 2010-05-19
US20030143162A1 (en) 2003-07-31
US20040265241A1 (en) 2004-12-30
DK1320355T3 (da) 2006-07-31
EP1320355A1 (de) 2003-06-25
ES2261735T3 (es) 2006-11-16
US20080095717A1 (en) 2008-04-24
US20050201947A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
DE60210402D1 (de) System zur Abgabe einer Tobramycin-Formulierung
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
NZ552047A (en) Method of treatment of endobronchial infections
IL139229A0 (en) Drug delivery system comprising a tightly compacted solid medicament stock
BR0109875A (pt) Tratamento de doenças respiratórias
EP0861667A3 (de) Partikelförmige Mittel
IL101056A (en) Composition for nasal treatment
MXPA03000353A (es) Medicamentos para tratamiento quimioterapeutico de enfermedades.
MY144021A (en) Pharmaceutical delivery system
EP3268010B1 (de) Zusammensetzungen aus gesäuertem nitrit, einem eisen-chelator und einem antibakteriellen wirkstoff zur behandlung von bakterieninfektionen
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU644094B2 (en) Medicaments
MXPA05009629A (es) Composiciones que contienen trospio.
BR9812553A (pt) Formulação medicamentosa com liberação de substância ativa controlada
DK98089D0 (da) Medikament-lipid-systemer med lav toxicitet
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
CA2564546A1 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
WO2005037256A3 (de) Flüssige zubereitung enthaltend tobramycin
NO20041011L (no) Inhaleringssammensetninger omfattende tricykliske 5,6-dihydro-9H-pyrazolo(3,4-C) -1,2,4-triazolo(4,3-alfa)pyridiner
AU2615795A (en) Compounds and compositions for administration via oral inhalation or insufflation
KR20090042507A (ko) 돼지 위축성 비염의 예방 및 치료를 위해 아미카신 및 이의약제학적으로 허용가능한 염과, 베타-글루칸을 유효성분을포함하는 비강 분무용 조성물
EP1347754A4 (de) Zusammensetzungen zur verhinderung der adhäsion
EP0753309A2 (de) Lactoferrin (oder analoge Proteine) und Desferrioxamine-Methansulfonate (oder andere Metalionenchelaten) Zusammensetzung für Therapie von viralen infektiösen Krankheiten
DE60202299D1 (de) Pharmazeutische zusammensetzung enthaltend salmeterol und budesonid zur behandlung von atemkrankheiten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1320355

Country of ref document: EP